(2R,3R)-3,5,7-trihydroxy-2-[(2R,3R)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-3,4-dihydro-2H-1-benzopyran-4-one

• ChemBase ID: 72982
• Molecular Formular: C25H22O10
• Molecular Mass: 482.43618
• Monoisotopic Mass: 482.1212969
• SMILES: [C@H]1([C@H](Oc2c(O1)ccc(c2)[C@@H]1[C@@H](O)C(=O)c2c(O1)cc(cc2O)O)c1ccc(c(c1)OC)O)CO
• Canonical SMILES: OC[C@H]1Oc2ccc(cc2O[C@@H]1c1ccc(c(c1)OC)O)[C@H]1Oc2cc(O)cc(c2C(=O)[C@@H]1O)O
• InChI: InChI=1S/C25H22O10/c1-32-17-6-11(2-4-14(17)28)24-20(10-26)33-16-5-3-12(7-18(16)34-24)25-23(31)22(30)21-15(29)8-13(27)9-19(21)35-25/h2-9,20,23-29,31H,10H2,1H3/t20-,23+,24-,25-/m1/s1
• InChIKey: SEBFKMXJBCUCAI-HKTJVKLFSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: (2R,3R)-3,5,7-trihydroxy-2-[(2R,3R)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-3,4-dihydro-2H-1-benzopyran-4-one
• IUPAC Traditional name: silibinin
• Synonyms: Silybin; Silibinin; (2R,3R)-3,5,7-trihydroxy-2-((2R,3R)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)chroman-4-one

Database IDs

• CAS Number: 22888-70-6
• PubChem SID: 162037902
• PubChem CID: 31553

CALCULATED PROPERTIES

• Acid pKa: 7.811773
• H Acceptors: 10
• H Donor: 5
• LogD (pH = 5.5): 2.6272182
• LogD (pH = 7.4): 2.4878588
• Log P: 2.629316
• Molar Refractivity: 120.2939 cm^3
• Polarizability: 46.884537 Å^3
• Polar Surface Area: 155.14 Å^2
• Rotatable Bonds: 4
• Lipinski's Rule of Five: true

PROPERTIES

Safety Information

• Storage Condition: -20°C

Product Information

• Salt Data: Free Base
• Classification: Genuine Natural Compounds

DETAILS

Selleck Chemicals - S2357

Research Area: Cancer
Biological Activity:
Silibinin(Silybin), also known as silybin, is the major active constituent of silymarin, the mixture of flavonolignans extracted from blessed milk thistle (Silybum marianum) consisting of silibinin A and B, isosibilinin A and B, silicristin, silidianin. Silymarin, as other flavonoids, has been shown to inhibit P-glycoprotein-mediated cellular efflux. The modulation of P-glycoprotein activity may result in altered absorption and bioavailability of drugs that are P-glycoprotein substrates. It has been reported that silymarin inhibit cytochrome P450 enzymes and an interaction with drugs primarily cleared by P450s cannot be excluded. [1]

REFERENCES

• http://en.wikipedia.org/wiki/Silibinin